Connor, Clark & Lunn Investment Management (CC&L)
BMY icon

Connor, Clark & Lunn Investment Management (CC&L)’s Bristol-Myers Squibb BMY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.8M Buy
+1,100,589
New +$64.2M 0.15% 142
2025
Q2 		– Sell
-17,279
Closed -$1.05M – 1516
2025
Q1 		$1.05M Sell
17,279
-169,116
-91% -$9.86M ﹤0.01% 926
2024
Q4 		$10.5M Buy
186,395
+117,224
+169% +$6.55M 0.05% 305
2024
Q3 		$3.58M Buy
+69,171
New +$3.24M 0.02% 522
2024
Q2 		– Sell
-40,873
Closed -$2.22M – 1396
2024
Q1 		$2.22M Sell
40,873
-1,461,160
-97% -$74.4M 0.01% 641
2023
Q4 		$77.1M Buy
1,502,033
+372,669
+33% +$19.6M 0.36% 64
2023
Q3 		$65.5M Buy
1,129,364
+1,089,745
+2,751% +$66.8M 0.34% 60
2023
Q2 		$2.53M Buy
39,619
+17,443
+79% +$1.17M 0.01% 548
2023
Q1 		$1.54M Sell
22,176
-462,302
-95% -$32.6M 0.01% 615
2022
Q4 		$34.9M Buy
484,478
+463,064
+2,162% +$34.9M 0.2% 85
2022
Q3 		$1.52M Sell
21,414
-246,540
-92% -$17.9M 0.01% 562
2022
Q2 		$20.6M Sell
267,954
-584,171
-69% -$44.5M 0.13% 128
2022
Q1 		$62.2M Buy
852,125
+120,249
+16% +$8.07M 0.31% 57
2021
Q4 		$45.6M Buy
731,876
+677,201
+1,239% +$39.7M 0.22% 86
2021
Q3 		$3.23M Buy
+54,675
New +$3.6M 0.02% 430
2020
Q4 		– Sell
-356,265
Closed -$21.5M – 902
2020
Q3 		$21.5M Sell
356,265
-426,395
-54% -$25.7M 0.14% 130
2020
Q2 		$46M Sell
782,660
-36,990
-5% -$2.21M 0.32% 67
2020
Q1 		$45.7M Buy
819,650
+815,944
+22,017% +$49.9M 0.41% 49
2019
Q4 		$238K Buy
+3,706
New +$212K ﹤0.01% 807
2019
Q3 		– Sell
-819,732
Closed -$37.2M – 967
2019
Q2 		$37.2M Buy
819,732
+10,975
+1% +$511K 0.24% 76
2019
Q1 		$38.6M Buy
808,757
+193,556
+31% +$9.64M 0.25% 73
2018
Q4 		$32M Buy
615,201
+84,560
+16% +$4.54M 0.22% 85
2018
Q3 		$32.9M Sell
530,641
-108,950
-17% -$6.47M 0.19% 96
2018
Q2 		$35.4M Buy
639,591
+169,875
+36% +$9.17M 0.2% 86
2018
Q1 		$29.7M Buy
469,716
+21,700
+5% +$1.4M 0.18% 108
2017
Q4 		$27.5M Buy
448,016
+2,175
+0.5% +$136K 0.16% 115
2017
Q3 		$28.4M Buy
445,841
+324,400
+267% +$18.9M 0.17% 99
2017
Q2 		$6.77M Sell
121,441
-53,525
-31% -$2.91M 0.04% 235
2017
Q1 		$9.52M Sell
174,966
-194,084
-53% -$10.6M 0.06% 183
2016
Q4 		$21.6M Buy
369,050
+39,500
+12% +$2.16M 0.15% 108
2016
Q3 		$17.8M Buy
329,550
+281,125
+581% +$18.1M 0.12% 127
2016
Q2 		$3.56M Buy
48,425
+15,425
+47% +$1.09M 0.03% 275
2016
Q1 		$2.11M Buy
+33,000
New +$2.08M 0.02% 326
2014
Q4 		– Sell
-104,976
Closed -$5.37M – 584
2014
Q3 		$5.37M Sell
104,976
-63,200
-38% -$3.16M 0.04% 133
2014
Q2 		$8.69M Buy
168,176
+160,000
+1,957% +$7.88M 0.06% 126
2014
Q1 		$469K Sell
8,176
-57,400
-88% -$3.05M ﹤0.01% 494
2013
Q4 		$3.7M Buy
+65,576
New +$3.34M 0.03% 184

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BMY Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 1,100,589 shares worth $66.8M. The stake represents 0.15% of the portfolio and ranks #142 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in BMY as recently as Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BMY in Q4 2013 and has held it in 37 quarters since. The position peaked at $77.1M in Q4 2023. 2,527 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 1,100,589 shares of Bristol-Myers Squibb worth $66.8M as of Q1 2026.
  • Bristol-Myers Squibb was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
  • Bristol-Myers Squibb made up 0.15% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #142 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 37 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Bristol-Myers Squibb position peaked at $77.1M in Q4 2023.
  • 2,527 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.